Early postprandial glucagon surge affects postprandial glucose levels in obese and non-obese patients with type 2 diabetes

被引:14
|
作者
Kozawa, Junji [1 ,2 ]
Okita, Kohei [1 ]
Iwahashi, Hiromi [1 ]
Yamagata, Kazuya [3 ]
Imagawa, Akihisa [1 ]
Shimomura, Iichiro [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Community Med, Suita, Osaka 5650871, Japan
[3] Kumamoto Univ, Fac Life Sci, Dept Med Biochem, Kumamoto 8608556, Japan
关键词
Type; 2; diabetes; Obesity; Glucagon; Incretin; ALPHA-CELL-FUNCTION; INSULIN; HYPERGLUCAGONEMIA; MODULATION; TOLERANCE; RELEASE; IMPACT;
D O I
10.1507/endocrj.EJ13-0018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Postprandial glucagon secretion was shown to be dysregulated in patients with type 2 diabetes. However, the differences in secretory patterns between obese and non-obese patients and their physiological effects on plasma glucose levels are not fully understood. This study population consisted of 21 (10 obese and 11 non-obese) consecutive patients with type 2 diabetes admitted for glycemic control. A 3-hour mixed-meal tolerance test was performed after glycemic control improved. Six non-diabetic subjects were also enrolled in the test. Postprandial glucagon levels increased after 30 min in diabetic patients but not in non-diabetic subjects. The glucagon levels in obese diabetic patients were significantly higher than those in non-obese diabetic patients, while the percent values of postprandial glucagon levels were not different between these groups. In diabetic patients, there were significant positive correlations between the percent value at 30 min and the early postprandial glucose levels at 0, 15 and 30 min and the areas under the curve (AUC(0-30) and AUC(30-90)). Interestingly, the ratio of this percent glucagon value to the C-peptide level at 30 mm was significantly associated with the late half of the postprandial glucose levels at 90, 120, 150 and 180 mm and the AUC(90-180). This is the first report that demonstrates the glucagon secretory patterns and the close correlations in detailed time course between the early postprandial glucagon response and the early and the late half of the postprandial glucose levels in obese and non-obese patients with type 2 diabetes.
引用
收藏
页码:813 / 818
页数:6
相关论文
共 50 条
  • [1] Fasting and postprandial acyl and desacyl ghrelin levels in obese and non-obese subjects
    Dardzinska, Jolanta Anna
    Malgorzewicz, Sylwia
    Kaska, Lukasz
    Proczko, Monika
    Stefaniak, Tomasz
    Stankiewicz, Marta
    Sledzinski, Zbigniew
    ENDOKRYNOLOGIA POLSKA, 2014, 65 (05) : 377 - 381
  • [2] Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
    Lund, Soren S.
    Tarnow, Lise
    Frandsen, Merete
    Smidt, Ulla M.
    Pedersen, Oluf
    Parving, Hans-Henrik
    Vaag, Allan A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (01) : 35 - 46
  • [3] DECREASED POSTPRANDIAL FGF-19 SERUM LEVELS IN NON-OBESE NAFLD PATIENTS
    Friedrich, D.
    Lammert, F.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S336 - S336
  • [4] Rosiglitazone is effective in obese and non-obese patients with Type 2 diabetes
    Deacon, L
    Donnelly, S
    Stewart, M
    Hand, L
    DIABETES, 2001, 50 : A433 - A433
  • [5] Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion
    Wägner, AM
    Ordóñez-Llanos, J
    Arcelus, R
    Bonet, R
    Jorba, O
    Sánchez-Quesada, JL
    Alonso, E
    Julve, J
    Pérez, A
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (08): : 1038 - 1042
  • [6] Serum levels of fibronectin and endothelin-1 in obese and non-obese patients with Type 2 diabetes mellitus
    Mogylnytska, L
    Mankovsky, B
    DIABETOLOGIA, 2004, 47 : A455 - A456
  • [7] Importance of Postprandial Glucose Levels in Type 2 Diabetes
    Bell, David S. H.
    SOUTHERN MEDICAL JOURNAL, 2009, 102 (05) : 553 - 553
  • [8] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Christophe Bardin
    Estelle Nobecourt
    Etienne Larger
    François Chast
    Jean-Marc Treluyer
    Saik Urien
    European Journal of Clinical Pharmacology, 2012, 68 : 961 - 968
  • [9] Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.
    Cranmer, H
    Jones, NP
    Patwardhan, R
    DIABETOLOGIA, 1999, 42 : A228 - A228
  • [10] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Bardin, Christophe
    Nobecourt, Estelle
    Larger, Etienne
    Chast, Francois
    Treluyer, Jean-Marc
    Urien, Saik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 961 - 968